<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03947814</url>
  </required_header>
  <id_info>
    <org_study_id>CR108616</org_study_id>
    <secondary_id>63623872FLZ1014</secondary_id>
    <secondary_id>2018-002818-12</secondary_id>
    <nct_id>NCT03947814</nct_id>
  </id_info>
  <brief_title>A Study of Orally Administered Pimodivir in Adult Participants With Renal Impairment</brief_title>
  <official_title>A Phase 1, Open-label, Single-dose, Parallel-group Study to Evaluate the Effect of Renal Impairment on the Pharmacokinetics of Pimodivir in Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen-Cilag International NV</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Janssen-Cilag International NV</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the pharmacokinetics (PK) of pimodivir after a&#xD;
      single oral dose of 600 milligrams (mg) in adult participants with severe renal impairment&#xD;
      who are not on dialysis and in adult participants with end-stage renal disease (ESRD) who are&#xD;
      not yet on dialysis compared to adult participants with normal renal function (Part A).&#xD;
      Optionally, to evaluate the PK in adult participants with mild and/or moderate renal&#xD;
      impairment compared to adult participants with normal renal function (Part B).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study 63623872FLZ1014 was terminated early based on a strategic business decision by Janssen to&#xD;
    end the clinical development program of JNJ-63623872.&#xD;
  </why_stopped>
  <start_date type="Actual">July 2, 2019</start_date>
  <completion_date type="Actual">September 9, 2020</completion_date>
  <primary_completion_date type="Actual">September 9, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Observed concentration (Cmax) of Pimodivir</measure>
    <time_frame>Predose (Day 1), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours postdose on Day 6</time_frame>
    <description>Cmax is the maximum observed concentration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under Curve From Time of Dosing to the Time of the last Measurable Concentration (AUC[0-last]) of Pimodivir</measure>
    <time_frame>Predose (Day 1), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours postdose on Day 6</time_frame>
    <description>AUC(0-last) is the AUC from time of dosing to the time of the last measurable (non-below quantification limit) concentration, calculated by linear-linear trapezoidal summation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC from time of dosing to infinity (AUC[0-infinity]) of Pimodivir</measure>
    <time_frame>Predose (Day 1), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours postdose on Day 6</time_frame>
    <description>AUC(0-infinity) is the AUC from time of dosing to infinity, calculated as AUC(0-last) + Clast/ (lambda[z]), where Clast is the last observed measurable concentration and lambda(z) is the apparent terminal elimination rate constant.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>Up to 42 (+/-) 2 days</time_frame>
    <description>An adverse event is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Kidney Failure, Chronic</condition>
  <arm_group>
    <arm_group_label>Part A: Normal renal function (control group)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with normal renal function (glomerular filtration rate [GFR] greater than or equal to [&gt;=] 90 milliliters per minute [mL/min]) will receive single oral dose of 600 mg pimodivir as 2*300 mg tablets.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: Severe renal impairment or ESRD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with severe renal impairment (GFR &gt;=15 to less than [&lt;]30 mL/min) who are not on dialysis or end stage renal disease (ESRD) (GFR &lt;15 mL/min) not yet on dialysis will receive single oral dose of 600 mg pimodivir as 2*300 mg tablets.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B (Optional): Mild renal impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with mild renal impairment (GFR &gt;=60 mL/min to &lt;90 mL/min) will receive single oral dose of 600 mg pimodivir as 2*300 mg tablets.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B (Optional): Moderate renal impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with moderate renal impairment (GFR &gt;=30 to &lt;60 mL/min) will receive single oral dose of 600 mg pimodivir as 2*300 mg tablets.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pimodivir</intervention_name>
    <description>Participants will receive single oral dose of 600 mg pimodivir as 2*300 mg tablets.</description>
    <arm_group_label>Part A: Normal renal function (control group)</arm_group_label>
    <arm_group_label>Part A: Severe renal impairment or ESRD</arm_group_label>
    <arm_group_label>Part B (Optional): Mild renal impairment</arm_group_label>
    <arm_group_label>Part B (Optional): Moderate renal impairment</arm_group_label>
    <other_name>JNJ-63623872</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participant must have a body mass index (Body Mass Index [BMI]; body weight (Kilograms&#xD;
             per height^2 [kg/m^2]) between 18.0 and 38.0 kg/m^2, inclusive, and body weight not&#xD;
             less than 50 kg, inclusive, at screening&#xD;
&#xD;
          -  Participants with normal renal function must have normal values for alanine&#xD;
             aminotransferase (ALT) and aspartate aminotransferase (AST) (less than or equal to&#xD;
             [&lt;=]1.5*upper limit of laboratory normal range [ULN]) at screening and Day -1 and&#xD;
             participants with renal impairment and end-stage renal disease (ESRD) must have values&#xD;
             for ALT and AST &lt;=3.0*ULN at screening and Day -1&#xD;
&#xD;
          -  Participants with normal renal function must have glomerular filtration rate (GFR)&#xD;
             greater than or equal to (&gt;=) 90 milliliters per minute (mL/min) and participants with&#xD;
             renal impairment (mild, moderate and severe) and ESRD must have &gt;=60 mL/min to &lt;90&#xD;
             mL/min (for Mild renal impairment); &gt;=30 to &lt;60 mL/min (for Moderate renal&#xD;
             impairment); &gt;=15 mL/min to &lt;30 mL/min (for Severe renal impairment not on dialysis);&#xD;
             and &lt;15 mL/min (for ESRD not on dialysis)&#xD;
&#xD;
          -  Participants with normal renal function must have a systolic blood pressure (after the&#xD;
             participant is supine for 5 minutes) between 90 millimeters of mercury (mmHg),&#xD;
             extremes included, and diastolic blood pressure no higher than 90 mmHg and&#xD;
             participants with renal impairment (mild, moderate and severe) and ESRD must have a&#xD;
             systolic blood pressure (after the participant is supine for 5 minutes) between 90 and&#xD;
             159 mmHg, extremes included, and diastolic blood pressure no higher than 99 mmHg. If&#xD;
             blood pressure is out of range, 1 repeated assessment is permitted after an additional&#xD;
             5 minutes of rest&#xD;
&#xD;
          -  A woman, except if postmenopausal, must have a negative highly sensitive serum&#xD;
             pregnancy test (beta human chorionic gonadotropin [beta hCG]) at screening and a&#xD;
             negative urine pregnancy test on Day -1&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participant has any surgical or medical condition that potentially may alter the&#xD;
             absorption, metabolism, or excretion of the study drug (for example [e.g.], Crohn's&#xD;
             disease), with the exception of renal impairment&#xD;
&#xD;
          -  Participant has a history of hepatitis B surface antigen (HBsAg) or hepatitis C virus&#xD;
             (HCV) antibody or any other clinically active liver disease at screening&#xD;
&#xD;
          -  Participant has a history of clinically significant drug allergy such as, but not&#xD;
             limited to, sulfonamides and penicillin, or drug allergy diagnosed in previous studies&#xD;
             with experimental drugs&#xD;
&#xD;
          -  Participant has known allergies, hypersensitivity, or intolerance to pimodivir or its&#xD;
             excipients&#xD;
&#xD;
          -  Participant has evidence of an active infection&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janssen-Cilag International NV Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Janssen-Cilag International NV</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CRS Clinical Research Services Kiel GmbH</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>APEX GmbH</name>
      <address>
        <city>Munchen</city>
        <zip>81241</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 10, 2019</study_first_submitted>
  <study_first_submitted_qc>May 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 13, 2019</study_first_posted>
  <last_update_submitted>May 31, 2021</last_update_submitted>
  <last_update_submitted_qc>May 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pimodivir,</keyword>
  <keyword>JNJ-63623872,</keyword>
  <keyword>Pharmacokinetics,</keyword>
  <keyword>Renal impairment,</keyword>
  <keyword>Kidney disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The data sharing policy of the Janssen Pharmaceutical Companies of Johnson &amp; Johnson is available at www.janssen.com/clinical-trials/transparency.&#xD;
As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu</ipd_description>
    <ipd_url>https://www.janssen.com/clinical-trials/transparency</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

